#Class Action #Denmark #Copenhagen #Berger Montague #Novo Nordisk

Important Class Action Alert for Novo Nordisk Investors

As the deadline for class action claims approaches, investors in Novo Nordisk A/S (NYSE: NVO) need to be vigilant. The firm Berger Montague PC is currently investigating claims of securities fraud against the global pharmaceutical giant. Investors who acquired Novo securities during the specified class period, from May 7, 2025, to July 28, 2025, may have the opportunity to seek representation as lead plaintiffs in this legal action, but they must act before the deadline of September 30, 2025.

Background of the Case

Novo Nordisk, known for its diabetes care medications, recently announced a downward adjustment in its sales and profit projections for the latter half of fiscal 2025. This announcement has raised concerns among investors, particularly due to factors such as the rising popularity of compounded GLP-1 medications, unexpected market slowdown, and intensified competition for its flagship products, Wegovy® and Ozempic®. Following these revelations, Novo's stock has seen a significant decline, which highlights the potential repercussions of the company's performance on its investors.

On July 29, 2025, the stock price fell dramatically from $69.00 to $53.94 per share, marking a staggering one-day drop of over 21%. This sharp decline has fueled the investigation, as many investors who purchased stocks during the class period may have faced substantial financial losses.

Legal Implications

Potential plaintiffs are encouraged to understand their rights promptly. This includes reviewing any communications received regarding the class action suit and determining if they qualify for representation. The attorneys at Berger Montague are dedicated to protecting the rights of investors and can provide valuable assistance to those affected by potentially misleading information from Novo Nordisk.

Investor Actions

If you are a holder of Novo's securities during the class period and wish to explore your legal options, you are encouraged to take immediate action. Provisions exist for those who may want to be appointed as lead plaintiffs, but the window for such opportunities is limited, thus acting promptly is essential.

For further inquiries, investors are advised to reach out to Andrew Abramowitz or Caitlin Adorni at Berger Montague. Contact details are as follows:

• - Andrew Abramowitz: [email protected] | (215) 875-3015
• - Caitlin Adorni: [email protected] | (267) 764-4865

About Berger Montague

Founded in 1970, Berger Montague has a long and esteemed track record in handling securities class action litigations in the United States. The firm's depth of experience has allowed it to represent both individual and institutional investors effectively over the decades. With offices across various major cities, Berger Montague is well-positioned to cater to the needs of investors nationwide.

Conclusion

As the September 30, 2025, deadline looms, impacted investors must stay informed and take advantage of the resources available to them. The forthcoming class action lawsuit against Novo Nordisk represents a crucial opportunity for those affected to seek restitution for their losses, but they must act before it's too late.